Abstract
Therapeutic efficiacy of the NMDA antagonist amantadine is reported in three acute neuroleptic free akinetic catatonic patients. Intravenous infusion of amantadine led to the resolution of catatonic symptoms and considerable reductions of scores in various motor scales (Simpson Angus scale for extrapyramidal side effects (SEPS), the abnormal involuntary movement scale (AIMS), Rogers catatonia and schizophrenia scales). The therapeutic effect of amantadine showed a characteristic temporal pattern with most pronounced effects four to six hours after administration and recurrence of catatonic symptoms by 24 hours later, at least partially. Such a temporal pattern of therapeutic efficacy and decreasing efficacy occurred in all three patients on all days. The results suggest the central importance of glutamatergic dysfunction in catatonic syndrome.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benes F. M., Vincent S. L., Alsterberg G., Bird E. D., SanGiovanni J. P. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci. 1992 Mar;12(3):924–929. doi: 10.1523/JNEUROSCI.12-03-00924.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Endicott J., Spitzer R. L., Fleiss J. L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976 Jun;33(6):766–771. doi: 10.1001/archpsyc.1976.01770060086012. [DOI] [PubMed] [Google Scholar]
- Gelenberg A. J. The catatonic syndrome. Lancet. 1976 Jun 19;1(7973):1339–1341. doi: 10.1016/s0140-6736(76)92669-6. [DOI] [PubMed] [Google Scholar]
- Goff D. C., Tsai G., Manoach D. S., Coyle J. T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995 Aug;152(8):1213–1215. doi: 10.1176/ajp.152.8.1213. [DOI] [PubMed] [Google Scholar]
- Greenamyre J. T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect. 1993;91(2-3):255–269. doi: 10.1007/BF01245235. [DOI] [PubMed] [Google Scholar]
- Kornhuber J., Weller M., Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect. 1993;6(1):63–72. doi: 10.1007/BF02252624. [DOI] [PubMed] [Google Scholar]
- Lund C. E., Mortimer A. M., Rogers D., McKenna P. J. Motor, volitional and behavioural disorders in schizophrenia. 1: Assessment using the Modified Rogers Scale. Br J Psychiatry. 1991 Mar;158:323-7, 333-6. doi: 10.1192/bjp.158.3.323. [DOI] [PubMed] [Google Scholar]
- Northoff G., Demisch L., Wenke J., Pflug B. Plasma homovanillic acid concentrations in catatonia. Biol Psychiatry. 1996 Mar 15;39(6):436–443. doi: 10.1016/0006-3223(95)00184-0. [DOI] [PubMed] [Google Scholar]
- Rosebush P. I., Hildebrand A. M., Furlong B. G., Mazurek M. F. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990 Sep;51(9):357–362. [PubMed] [Google Scholar]
- Simpson G. M., Angus J. W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19. doi: 10.1111/j.1600-0447.1970.tb02066.x. [DOI] [PubMed] [Google Scholar]
- Starkstein S. E., Petracca G., Tesón A., Chemerinski E., Merello M., Migliorelli R., Leiguarda R. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry. 1996 Mar;60(3):326–332. doi: 10.1136/jnnp.60.3.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tsai G., Passani L. A., Slusher B. S., Carter R., Baer L., Kleinman J. E., Coyle J. T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995 Oct;52(10):829–836. doi: 10.1001/archpsyc.1995.03950220039008. [DOI] [PubMed] [Google Scholar]